NCT01517529View on ClinicalTrials.gov

Evaluating the Role of Immune Responses in the Emergence of Protease Inhibitor Mutations

CompletedOBSERVATIONAL
Enrollment

10

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

July 31, 2014

Study Completion Date

December 31, 2014

Conditions
Hepatitis C
Trial Locations (1)

45267

University of Cincinnati, Cincinnati

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Cincinnati

OTHER

NCT01517529 - Evaluating the Role of Immune Responses in the Emergence of Protease Inhibitor Mutations | Biotech Hunter | Biotech Hunter